Thrombodynamics—A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment
Balandina A. N., Serebriyskiy I. I., Poletaev A. V., Polokhov D. M., Gracheva M. A., Koltsova E. M., Vardanyan D. M., Taranenko I. A., Kry'lov A. Yu., Urnova E. S., Lobastov K. V., Chernyakov A. V., Shulutko E. M., Momot A. P., Shulutko A. M., Ataullakhanov F. I.
PLoS ONE
Vol.13, Issue6, Num.e0199900
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1371/journal.pone.0199900
Аннотация:
Background Heparin therapy and prophylaxis may be accompanied by bleeding and thrombotic complications due to individual responses to treatment. Dosage control based on standard laboratory assays poorly reflects the effect of the therapy. The aim of our work was to compare the heparin sensitivity of new thrombodynamics (TD) assay with sensitivity of other standard and global coagulation tests available to date. Study population and methods A total of 296 patients with high risk of venous thromboembolism (deep vein thrombosis (DVT), early postoperative period, hemoblastosis) were enrolled in the study. We used a case-crossover design to evaluate the sensitivity of new thrombodynamics assay (TD) to the hemostatic state before and after unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) therapy/prophylaxis and to compare it with the activated partial thromboplastin time (APTT), anti-Xa activity test, thrombin generation test (TGT) and thromboelastography (TEG). A receive
Ключевые слова:
blood clotting factor 10a; D dimer; heparin; anticoagulant agent; heparin; activated partial thromboplastin time; adult; aged; anticoagulant therapy; Article; blood clotting disorder; blood clotting test; blood sampling; case control study; continuous infusion; controlled study; crossover procedure; deep vein thrombosis; drug blood level; drug monitoring; female; human; major clinical study; male; predictive value; sensitivity and specificity; thrombin time; thrombodynamics assay; thromboelastography; thrombosis prevention; venous thromboembolism; blood; comparative study; cross-sectional study; drug monitoring; middle aged; partial thromboplastin time; procedures; vein thrombosis; Adult; Aged; Anticoagulants; Cross-Sectional Studies; Drug Monitoring; Female; Heparin; Humans; Male; Middle Aged; Partial Thromboplastin Time; Thrombelastography; Venous Thrombosis
Язык текста: Английский
ISSN: 1932-6203
Balandina A. N.
Serebriyskiy I. I.
Poletaev A. V.
Polokhov D. M.
Gracheva M. A.
Koltsova E. M.
Vardanyan D. M.
Taranenko I. A.
Kry'lov A. Yu. Aleksej Yuryevich 1964-
Urnova E. S.
Lobastov K. V.
Chernyakov A. V.
Shulutko E. M.
Momot A. P.
Shulutko A. M. Aleksandr Mikhaylovich 1950-
Ataullakhanov F. I.
Баландина А. Н.
Серебриyскиy И. И.
Полетаев А. В.
Полохов Д. М.
Грачева М. А.
Кольцова Е. М.
Варданян Д. М.
Тараненко И. А.
Крылов А. Ю. Алексей Юрьевич 1964-
Урнова Е. С.
Лобастов К. В.
Черняков А. В.
Шулутко Е. М.
Момот А. П.
Шулутко А. М. Александр Михайлович 1950-
Атауллаханов Ф. И.
Thrombodynamics—A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment
Текст визуальный непосредственный
PLoS ONE
Vol.13, Issue6 Num.e0199900
2018
Статья
blood clotting factor 10a D dimer heparin anticoagulant agent heparin activated partial thromboplastin time adult aged anticoagulant therapy Article blood clotting disorder blood clotting test blood sampling case control study continuous infusion controlled study crossover procedure deep vein thrombosis drug blood level drug monitoring female human major clinical study male predictive value sensitivity and specificity thrombin time thrombodynamics assay thromboelastography thrombosis prevention venous thromboembolism blood comparative study cross-sectional study drug monitoring middle aged partial thromboplastin time procedures vein thrombosis Adult Aged Anticoagulants Cross-Sectional Studies Drug Monitoring Female Heparin Humans Male Middle Aged Partial Thromboplastin Time Thrombelastography Venous Thrombosis
Background Heparin therapy and prophylaxis may be accompanied by bleeding and thrombotic complications due to individual responses to treatment. Dosage control based on standard laboratory assays poorly reflects the effect of the therapy. The aim of our work was to compare the heparin sensitivity of new thrombodynamics (TD) assay with sensitivity of other standard and global coagulation tests available to date. Study population and methods A total of 296 patients with high risk of venous thromboembolism (deep vein thrombosis (DVT), early postoperative period, hemoblastosis) were enrolled in the study. We used a case-crossover design to evaluate the sensitivity of new thrombodynamics assay (TD) to the hemostatic state before and after unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) therapy/prophylaxis and to compare it with the activated partial thromboplastin time (APTT), anti-Xa activity test, thrombin generation test (TGT) and thromboelastography (TEG). A receive